Hydrochlorothiazide

DRUG INFORMATION

  ADULT
    - Adults: For Edema: The usual adult dosage is 25 mg to 100 mg daily as a single or
      divided dose.
      Source: US FDA label for hydrochlorothiazide (Hydrochlorothiazide), section
      'dosage and administration', retrieved 2026-08-29
    - For Control of Hypertension: The usual initial dose in adults is 25 mg daily given
      as a single dose.
      Source: US FDA label for hydrochlorothiazide (Hydrochlorothiazide), section
      'dosage and administration', retrieved 2026-08-29
    - The dose may be increased to 50 mg daily, given as a single or two divided doses.
      Source: US FDA label for hydrochlorothiazide (Hydrochlorothiazide), section
      'dosage and administration', retrieved 2026-08-29

  CHILD
    - There are no well-controlled clinical trials in pediatric patients. Information on
      dosing in this age group is supported by evidence from empiric use in pediatric
      patients and published literature regarding the treatment of hypertension in such
      patients. (See DOSAGE AND ADMINISTRATION: Infants and Children ).
      Source: US FDA label for hydrochlorothiazide (Hydrochlorothiazide), section
      'pediatric use', retrieved 2026-08-29
    - Therapy should be individualized according to patient response. Use the smallest
      dosage necessary to achieve the required response. Adults: For Edema: The usual
      adult dosage is 25 mg to 100 mg daily as a single or divided dose. Many patients
      with edema respond to intermittent therapy, i.e., administration on alternate days
      or on three to five days each week.
      Source: US FDA label for hydrochlorothiazide (Hydrochlorothiazide), section
      'dosage and administration', retrieved 2026-08-29
    - Infants and Children: For Diuresis and For Control of Hypertension: The usual
      pediatric dosage is 0.5 to 1 mg per pound (1 to 2 mg/kg) per day in single or two
      divided doses, not to exceed 37.5 mg per day in infants up to 2 years of age or
      100 mg per day in children 2 to 12 years of age.
      Source: US FDA label for hydrochlorothiazide (Hydrochlorothiazide), section
      'dosage and administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for hydrochlorothiazide
      (Hydrochlorothiazide), retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for hydrochlorothiazide
      (Hydrochlorothiazide), retrieved 2026-08-29

  PREGNANCY   [ CAUTION ]
    The label allows it only when the benefit is judged to outweigh the risk. Read the
      quote below.
    - Pregnancy Category B Studies in which hydrochlorothiazide was orally administered
      to pregnant mice and rats during their respective periods of major organogenesis
      at doses up to 3000 and 1000 mg hydrochlorothiazide/kg, respectively, provided no
      evidence of harm to the fetus.
      Source: US FDA label for hydrochlorothiazide (Hydrochlorothiazide), section
      'pregnancy', retrieved 2026-08-29
    - There are, however, no adequate and well-controlled studies in pregnant women.
      Source: US FDA label for hydrochlorothiazide (Hydrochlorothiazide), section
      'pregnancy', retrieved 2026-08-29
    - Because animal reproduction studies are not always predictive of human response,
      this drug should be used during pregnancy only if clearly needed.
      Source: US FDA label for hydrochlorothiazide (Hydrochlorothiazide), section
      'pregnancy', retrieved 2026-08-29

  BREASTFEEDING
    - Because of the potential for serious adverse reactions in nursing infants, a
      decision should be made whether to discontinue nursing or to discontinue
      hydrochlorothiazide, taking into account the importance of the drug to the mother.
      Source: US FDA label for hydrochlorothiazide (Hydrochlorothiazide), section
      'nursing mothers', retrieved 2026-08-29